



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, March 10th 2016
7:15 a.m. to 8:15 a.m.
Cannon Health Building
Room 125

Board Members Present

Jay Aldus, D.D.S

Ben Berrett, Pharm.D.

Neal Catalano, Pharm.D.

Holly Gurgle, Pharm.D.

Keith Tolman, M.D.

Jennifer Brinton, M.D., Board Chair

Susan Siegfried, M.D

Kumar Shah, M.Sc., P.Eng.

Katherine Smith, Pharm.D.

Michael Symond, M.D.

Board Members Excused:

Steve Lore, M.D

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, Pharm.D.

Robyn Seely, Pharm.D.

Bryan Larson, Pharm.D.

Megan Schlappi, C.Ph.T.

Heather Santacruz, R.N.

Alyssa Pitts, R.N.

Merelynn Berrett, R.N

Other Individuals Present:

Joanita Lake, UofU*

Robert Nohaver, UofU Health Plans

Christopher Valentine, Health Choice

Michele Puyear, Gilead

Julie Ewing, Department of Health

Matt Michel, Select Health

Benjamin Schatzman, Molina

Laura Britton, Healthy U

Mindy Peterson, UofU

Anji Petrizzo, Select Health

Lynsey Spence, Stat Auditing Department

Russ Elbel, Select Health

*UofU = University of Utah

Cody Ball, Select Health

Hal Gooch, Molina

Lori Howarth, Bayer

Roy Gandolfi, Select Health

Kylan Brown, State Auditing Department

Lin Jenson, Gilead

Michelle Bice, Gilead

Ryan Morris, Bayer

Eric Cannon, Select Health

Russell Vinik, UofU

Nick Purse, State Auditing Department

James Shea, Gilead

Meeting conducted by: Jennifer Brinton, M.D.

1. Welcome & Housekeeping:

- a) Jennifer Brinton opened the meeting. Robyn Seely made housekeeping announcements.
- b) Motion: Approve the February meeting minutes. Motioned by Kumar Shah, seconded by Neal Catalano. Affirmed unanimously.

2. Introduction: Hepatitis C Treatments

- a) Chad Hope introduced the reason for re-visiting the topic. In November 2015, CMS issued a letter to the States via the drug rebate program. The letter contained guidance to the States regarding CMS' views of appropriate and inappropriate PA criteria for Hepatitis C virus (HCV) treatments. Utah Medicaid's current criteria-diagnosis of hepatitis C and genotype testing- meet CMS' suggestions. The purpose of this meeting is to revisit the criteria to determine if it should remain the same or be changed.
- b) Keith Tolman reminded the Board that two new HCV treatments have been recently approved.

3. Comments from the Utah Medicaid Accountable Care Organizations:

- a) Healthy U: Laura Britton, practicing pharmacist, read portions of the statement from the Utah Coalition of Medicaid Health Plans.
- b) Health Choice Utah: Christopher Valentine, practicing physician and Medical Director for Health Choice Utah, address patient compliance and the need for case management.
- c) Molina: Ben Schatzman, Vice President of Pharmacy Health Plans, observed that Utah is the only State considering changes in criteria as a result of the CMS letter.
- d) Select Health: Roy Gandolfi, practicing internist and Medical Director of Select Health, addressed patient prioritization. He summarized some points from a letter written to himself by Michael Charlton. Michael Charlton is a physician in Utah who has previously appeared before the Board and who participates in composing HCV treatment guidelines for the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.

4. Public Comments: Michele Puyear, pharmacist, yielded her time.

5. Board Discussion

- a) Keith Tolman suggested that having the HCV genotype should be a required for HCV treatment.
- b) The role of specialists, generalists and other practitioners in HCV treatment were discussed.
- c) The quickly evolving drug market, and how Medicaid policy can keep up, was discussed.
- d) The challenge of choosing the most appropriate regimen was discussed.
- e) Motion: Include the following wording in HCV PA criteria: Prescriber is or has consulted with an expert in treating Hepatitis C. An expert was defined as a gastroenterologist, hepatologist, infectious disease physician, or a mid-level practitioner working in collaboration with any of the former. Motion by Neal Catalano, seconded by Susan Siegfried. Affirmed unanimously.
- f) The challenge of prioritizing patients was discussed. Jennifer Brinton invited Dr. Gandolfi to come forward and answer more questions from the Board. He summarized Select Health's HCV PA criteria.
- g) Jennifer Brinton invited any attendees who wished to comment to come forward. Russel Vinik practicing internist suggested excluding portal hypertension from the criteria.
- h) Motion: Require the following in HCV drug criteria: Evidence of fibrosis without evidence of liver failure or extrahepatic manifestations (with or without evidence of liver failure). Motioned by Keith Tolman, seconded by Mike Symond. Affirmed unanimously.
- i) The two motions above will be added to the current requirements that the drug is indicated for the patient's genotype and that FDA-required concurrent therapies are prescribed. Motion by Keith Tolman, seconded by Mike Symond. Affirmed unanimously.

6. Public Meeting Adjourned

- a) Jay Aldous motioned to close the meeting, Neal Catalano seconded. Affirmed unanimously.

7. Board Review of Patient-Specific Prior Authorization requests

- a) Two petitions were considered, one was denied and the other was approved.

Minutes prepared by Robyn Seely, PharmD

Recording available upon request, send email to medicaidpharmacy@utah.gov